Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
基本信息
- 批准号:10468845
- 负责人:
- 金额:$ 8.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-13 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Lung InjuryAcute Renal Failure with Renal Papillary NecrosisAdmission activityAreaArrhythmiaAttenuatedBedsBile AcidsBloodBlood PlateletsCOVID-19CardiacCardiomyopathiesCardiovascular systemCatchment AreaCenter for Translational Science ActivitiesChildChildhoodCirrhosisClinical MedicineClinical ResearchClinical TrialsClinical Trials Data Monitoring CommitteesCollaborationsCommunitiesContractsCritical CareCritical IllnessDataData Coordinating CenterDevelopmentDigestive System DisordersDiseaseDrug KineticsEndotheliumEnrollmentEthicsEthnic OriginExtramural ActivitiesFacultyFamily suidaeFosteringFunctional disorderFundingGoalsGood Clinical PracticeGrantHeartHematologyHispanicHospitalsImmuneImmune System DiseasesIndividualInfantInflammationInflammatoryIntensive CareInternationalIntervention TrialInvestigational DrugsKidneyLeadershipLeukocytesLifeLiverLiver FailureMedical centerMedicineMentorsMissionModelingMorbidity - disease rateMulti-Institutional Clinical TrialMulticenter TrialsMultiple Organ FailureMyocardialNational Institute of Child Health and Human DevelopmentNeonatalNephrologyOncologyOperative Surgical ProceduresOrganOutcomePathologicPatientsPediatric Acute Lung InjuryPediatric HospitalsPerformancePersonsPhenotypePopulationPopulation HeterogeneityPrincipal InvestigatorProceduresProteinsProtocols documentationPublicationsRandomizedRecording of previous eventsReportingResearchResearch InstituteResearch PersonnelResearch Project GrantsResearch TrainingResourcesRespiratory DiaphragmSECTM1 geneScientistSepsisServicesSiteSystemTalentsTechniquesTexasTherapeutic AgentsThrombosisTrainingTraining ProgramsTranslational ResearchUnited StatesUnited States Food and Drug AdministrationUnited States National Institutes of HealthWorkcareer developmentclinical research sitecohortcollegeethnic diversityexpectationimmunoregulationimproved outcomeinnovationmachine learning algorithmmechanical circulatory supportmedical specialtiesmeetingsmortalitynewsnovelnovel therapeuticsparticipant enrollmentpediatric departmentporcine modelpre-clinicalprogramsprospectiveseptic patientssuccess
项目摘要
PROJECT SUMMARY/ABSTRACT – Baylor College of Medicine/Texas Children's Hospital
The goals of the current proposal are to reorganize and expand the Collaborative Pediatric Critical Care
Research Network (CPCCRN), to mentor young investigators in CPCCRN to become independent
investigators, and to implement the multi-center randomized controlled “Personalized Immunomodulation in
Sepsis-Induced Multiple Organ Dysfunction” interventional trial. The newly organized CPCCRN will expand
from 7 to 24 clinical sites (12 Primary and 12 Ancillary sites), which will be the largest NIH Pediatric Critical
Care Research Network to date. We at Baylor College of Medicine (BCM) - Texas Children's Hospital (TCH;
Primary Site) and Children's Hospital of San Antonio (CHofSA; Ancillary Site) are very enthusiastic about
participating as new sites. TCH is the largest freestanding children's hospital system in the U.S. and is one of
the best (Rank #4 Children's Hospital by U.S. News & World Report 2020-2021). We have every pediatric
subspecialty and offer every service expected in a quaternary pediatric center. We have an extensive track
record of successful collaboration in multi-center clinical trials such as the Pediatric Acute Lung Injury and
Sepsis Investigators and the Pediatric Heart Network. In combination with our CHofSA partner, we will provide
access to 163+24 beds with 6000 annual admissions, enabling us to participate fully in the “Personalized
Immunomodulation in Sepsis-induced Multiple Organ Dysfunction (MODS)” trial described in the Overall
Component of this application. Our sites have several highly talented young faculty, who have career
development grants with innovative translational research projects, and will contribute to the success of
CPCCRN. For example, Dr. Desai (K12 recipient) pioneered the field of pediatric cirrhotic cardiomyopathy and
bile acid-myocardial interaction (cholecardia). His aim is to improve outcomes of pediatric liver failure through
decreasing circulating pathologic bile acids by novel bile acid sequestrants and blood purification techniques.
Dr. Lam (K08 recipient) develops novel protein to attenuate inflammation through inhibiting leukocyte-platelet-
endothelial interactions. His aim is to improve outcomes in pediatric liver failure and more recently, COVID19-
induced inflammation. Dr. Nguyen, our Co-Investigator, is R01 funded to study mechanisms of sepsis-induced
MODS and to develop targeted novel agent for this deadly disease. His aim is to obtain Investigational New
Drug status for his novel A2 Protein from the Food and Drug Administration, and subsequently, to enter A2
Protein in clinical trials such as CPCCRN. Dr. Arikan, our site Principle Investigator, plans to study the impact
of extracorporeal therapies in immunomodulation and pharmacokinetics of novel therapeutics to build on her
previous work in pediatric MODS with a special emphasis on interaction of acute kidney injury, acquired
immune dysfunction, and MODS phenotypes.
项目概要/摘要-贝勒医学院/德克萨斯儿童医院
当前提案的目标是重组和扩大协作儿科重症监护
研究网络(CPCCRN),指导CPCCRN的年轻研究人员成为独立的研究人员
研究者,并实施多中心随机对照“个性化免疫调节,
脓毒症诱导的多器官功能障碍”干预性试验。新组建的CPCCRN将扩大
从7到24个临床研究中心(12个主要研究中心和12个辅助研究中心),这将是美国国立卫生研究院最大的儿科危重病研究中心。
研究网络至今。我们在贝勒医学院(Baylor College of Medicine)-德克萨斯儿童医院(Texas Children's Hospital;
主站点)和圣安东尼奥儿童医院(CHofSA;辅助站点)非常热衷于
作为新网站参与。TCH是美国最大的独立儿童医院系统,也是美国最大的儿童医院之一。
最好的(2020-2021年《美国新闻与世界报道》排名第四的儿童医院)。我们有所有的儿科医生
专科,并提供在四级儿科中心预期的所有服务。我们有一个广泛的轨道
在多中心临床试验中的成功合作记录,如儿科急性肺损伤和
败血症研究者和儿科心脏网络。与我们的CHofSA合作伙伴一起,我们将提供
获得163+24张病床,每年6000人次,使我们能够充分参与“个性化”
免疫调节在脓毒症诱导的多器官功能障碍(MODS)中的作用
组件。我们的网站有几个非常有才华的年轻教师,谁拥有职业生涯
发展赠款与创新的转化研究项目,并将有助于成功的
CPCCRN。例如,Desai博士(K12受体)开创了儿童缺血性心肌病领域,
胆汁酸-心肌相互作用(胆心)。他的目标是通过以下方法改善小儿肝功能衰竭的预后:
通过新的胆汁酸螯合剂和血液净化技术减少循环病理性胆汁酸。
博士Lam(K 08受体)开发了一种新的蛋白质,通过抑制白细胞-血小板-
内皮细胞相互作用他的目标是改善儿童肝功能衰竭的预后,最近,COVID 19-
诱发炎症。阮博士,我们的合作研究者,是R 01资助研究脓毒症诱导的机制,
MODS,并开发针对这种致命疾病的靶向新药。他的目标是获得新的研究
药物状态为他的新A2蛋白从食品和药物管理局,并随后,进入A2
临床试验中的蛋白质,如CPCCRN。Arikan博士,我们的研究中心首席研究员,计划研究
体外治疗的免疫调节和药代动力学的新疗法,以建立在她的
以前在儿科MODS中的工作,特别强调急性肾损伤,获得性
免疫功能障碍和MODS表型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ayse Akcan Arikan其他文献
Ayse Akcan Arikan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ayse Akcan Arikan', 18)}}的其他基金
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
- 批准号:
10670228 - 财政年份:2021
- 资助金额:
$ 8.43万 - 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
- 批准号:
10667491 - 财政年份:2021
- 资助金额:
$ 8.43万 - 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
- 批准号:
10248814 - 财政年份:2021
- 资助金额:
$ 8.43万 - 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
- 批准号:
10393794 - 财政年份:2021
- 资助金额:
$ 8.43万 - 项目类别:
Collaborative Pediatric Critical Care Research Network - Clinical Site
儿科重症监护协作研究网络 - 临床网站
- 批准号:
10470941 - 财政年份:2021
- 资助金额:
$ 8.43万 - 项目类别:
Pediatric Paracorporeal and Extracorporeal Therapies (PPET) Summit 2021
2021 年儿科体外和体外治疗 (PPET) 峰会
- 批准号:
10156359 - 财政年份:2020
- 资助金额:
$ 8.43万 - 项目类别: